References
- Weiss J, Sos ML, Seidel D et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med.2(62), 62ra93 (2010).
- Dutt A, Ramos AH, Hammerman PS et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE6(6), e20351 (2011).
- Hammerman PS, Sos ML, Ramos AH et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov.1(1), 78–89 (2011).
- Camidge DR, Bang Y, Kwak EL et al. Progression-free survival (PFS) from a Phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J. Clin. Oncol.29(Suppl.), (2011) (Abstract 2501).
- Crinò L, Kim D, Riely GJ et al. Initial Phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J. Clin. Oncol.29(Suppl.), (2011) (Abstract 7514).
- Choi YL, Soda M, Yamashita Y et al.EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med.363(18), 1734–1739 (2010).
- Sasaki T, Koivunen J, Ogino A et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res.71(18), 6051–6060 (2011).
- Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res.18(5), 1472–1482 (2012).
- Katayama R, Shaw AT, Khan TM et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med.4(120), 120ra17 (2012).
- D’Addario G, Früh M, Reck M et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol.21(Suppl. 5), v116–v119 (2010).
- Soria JC, Mauguen A, Reck M et al. Meta-analysis of randomized Phase II/III trials adding bevacizumab to platin-based chemotherapy as 1st-line treatment in patients with advanced non-small cell lung cancer (NSCLC). Ann. Oncol.21(Suppl. 8), (2010) (Abstract 437P).
- Reck M, Barlesi F, Crinò L et al. Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann. Oncol.23(5), 1111–1120 (2011).
- Mok T, Gorbunova V, Juhasz E et al. Biomarker analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin–Gemcitabine (CG) or Carboplatin–Paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC). Presented at: 16th European Multidisciplinary Cancer Congress. Stockolm, Sweden, 23–27 September 2011.
- Hilbe W, Manegold C, Pircher A. Targeting angiogenesis in lung cancer – pitfalls in drug development. Transl. Lung Cancer Res. doi:10.3978/j.issn.2218–6751.2012.01.01 (2012) (Epub ahead of print).
- Novello S, Ramlau R, Gorbunova VA et al. Aflibercept in combination with docetaxel for second-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC): final results of a multinational placebo-controlled Phase III trial (EFC10261-VITAL). Presented at: 14th World Conference of Lung Cancer. Amsterdam, The Netherlands, 4–7 July 2011.
- Hilberg F, Roth GJ, Krssak M et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res.68(12), 4774–4782 (2008).
- Garassino MC, Marabese M, Rusconi P et al. Different types of K-RAS mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann. Oncol.22(1), 235–237 (2011).
- Ihle NT, Byers LA, Kim ES et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl Cancer Inst.104(3), 228–239 (2012).
- Paik PK, Arcila ME, Fara M et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J. Clin. Oncol.29(15), 2046–2051 (2011).
Websites
- ClinicalTrials.gov. An Investigational Drug, PF-02341066 is Being Studied Versus Standard of Care in Patients with Advanced Non-Small Cell Lung Cancer with a Specific Gene Profile Involving the Anaplastic Lymphoma Kinase (ALK) Gene. http://clinicaltrials.gov/ct2/results?term=NCT00932893 (Accessed 15 March 2012)
- ClinicalTrials.gov. A Clinical Trial Testing the Efficacy of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin or Carboplatin in Patients with ALK Positive Non Squamous Cancer of the Lung. http://clinicaltrials.gov/ct2/results?term=NCT01154140 (Accessed 15 March 2012)
- ClinicalTrials.gov. LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer. http://clinicaltrials.gov/ct2/results?term=NCT00805194 (Accessed 15 March 2012)
- ClinicalTrials.gov. Lume Lung 2: BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC. http://clinicaltrials.gov/ct2/results?term=NCT00806819 (Accessed 15 March 2012)
- ClinicalTrials.gov. Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients. http://clinicaltrials.gov/ct2/results?term=NCT00890825 (Accessed 15 March 2012)
- ClinicalTrials.gov. A Phase II Study of the Selective BRAF Kinase Inhibitor GSK2118436 in Subjects With Advanced Non-small Cell Lung Cancer and BRAF Mutations. http://clinicaltrials.gov/ct2/results?term=NCT01336634 (Accessed 15 March 2012)